Plasma protein binding of drugs is a well-recognised phenomena, but it is only recently that
the implications for drug action in vivo have been fully appreciated. Plasma proteins, by …

It is a commonly accepted assumption that only unbound drug molecules are available to
interact with their targets. Therefore, one of the objectives in drug design is to optimize the …

Plasma protein binding (PPB) strongly affects drug distribution and pharmacokinetic
behavior with consequences in overall pharmacological action. Extended plasma protein …

The discovery and development of a new drug are time-consuming, difficult and expensive.
This complex process has evolved from classical methods into an integration of modern …

One of the many factors involved in determining the distribution and metabolism of a
compound is the strength of its binding to human serum albumin. While experimental and …

Chemokines CXCL8 and CXCL1 play a key role in the recruitment of neutrophils at the site
of inflammation. CXCL8 binds two membrane receptors, CXCR1 and CXCR2, whereas …

The effects of low-molecular-weight (< 1000 g/mol) chemicals on biosystems ranging from
membranes to organisms are of interest in medicinal chemistry, chemical biology …

It is a commonly accepted assumption that only unbound drug molecules are available to
interact with their targets. In order to achieve high unbound plasma drug concentration, it …

Models for the prediction of blood-brain partitioning (logBB) and human serum albumin
binding (logK (HSA)) of neutral molecules were developed using the set of 5 COSMO-RS σ …

Introduction: Binding of drugs to human serum albumin (HSA) strongly influences their
pharmacokinetic behavior and is associated with drug safety issues, low clearance, low …